CDKN2A
嫌色细胞
BAP1型
生物
肾细胞癌
癌症研究
肾透明细胞癌
PTEN公司
清除单元格
肾癌
癌症
肿瘤科
病理
医学
PI3K/AKT/mTOR通路
遗传学
黑色素瘤
信号转导
作者
C. Ricketts,Aguirre A. de Cubas,Huihui Fan,Christof C. Smith,Martin Lang,Ed Reznik,Reanne Bowlby,Ewan A. Gibb,Rehan Akbani,Rameen Beroukhim,Donald P. Bottaro,Toni K. Choueiri,Richard A. Gibbs,Andrew K. Godwin,Scott M. Haake,A. Ari Hakimi,Elizabeth P. Henske,James J. Hsieh,Thai H. Ho,Rupa S. Kanchi
出处
期刊:Cell Reports
[Cell Press]
日期:2018-04-01
卷期号:23 (1): 313-326.e5
被引量:650
标识
DOI:10.1016/j.celrep.2018.03.075
摘要
Renal cell carcinoma (RCC) is not a single disease, but several histologically defined cancers with different genetic drivers, clinical courses, and therapeutic responses. The current study evaluated 843 RCC from the three major histologic subtypes, including 488 clear cell RCC, 274 papillary RCC, and 81 chromophobe RCC. Comprehensive genomic and phenotypic analysis of the RCC subtypes reveals distinctive features of each subtype that provide the foundation for the development of subtype-specific therapeutic and management strategies for patients affected with these cancers. Somatic alteration of BAP1, PBRM1, and PTEN and altered metabolic pathways correlated with subtype-specific decreased survival, while CDKN2A alteration, increased DNA hypermethylation, and increases in the immune-related Th2 gene expression signature correlated with decreased survival within all major histologic subtypes. CIMP-RCC demonstrated an increased immune signature, and a uniform and distinct metabolic expression pattern identified a subset of metabolically divergent (MD) ChRCC that associated with extremely poor survival.
科研通智能强力驱动
Strongly Powered by AbleSci AI